[68Ga]Ga-PSMA-11

DRUG6 trials

Conditions

HCC - Hepatocellular CarcinomaMetastatic Castration-Resistant Prostate Cancer (mCRPC)Metastatic Neuroendocrine Prostate CancerPET/CTProstate CancerProstatic NeoplasmsRecurrence

Early Phase 1

Head-to-head Comparison of [68Ga]Ga-PSMA-D5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

NCT05955677

Anhui Provincial HospitalPET/CT, Prostate Cancer

Start: 2023-07-10End: 2024-12-31Target: 100Updated: 2023-07-21

Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

RecruitingNCT06462508

Anhui Provincial HospitalPET/CT, Prostate Cancer

Start: 2024-04-20End: 2025-12-31Target: 30Updated: 2024-06-17

Phase 1

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruitingNCT06379217

Novartis PharmaceuticalsMetastatic Neuroendocrine Prostate Cancer

Start: 2024-07-29End: 2026-08-27Updated: 2026-03-11

Phase 2

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Active, not recruitingNCT05658003

Novartis PharmaceuticalsMetastatic Castration-Resistant Prostate Cancer (mCRPC)

Start: 2023-05-05End: 2027-01-13Updated: 2026-03-23

Phase 3

Study of Diagnostic Performance of [18F]CTT1057 in BCR

CompletedNCT04838613

Novartis PharmaceuticalsProstate Cancer, Prostatic Neoplasms, Recurrence

Start: 2021-09-30End: 2023-11-23Updated: 2025-10-20

Unknown Phase

[68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.

RecruitingNCT06999837

Nantes University HospitalHCC - Hepatocellular Carcinoma

Start: 2025-09-23End: 2027-09-23Target: 40Updated: 2025-10-07

Related Papers

Imaging Efficacy of [<sup>18</sup>F]CTT1057 PET/CT in Patients with Biochemically Recurrent Prostate Cancer: Results from GuidePath—A Phase 3, Prospective Multicenter Study

Journal of Nuclear Medicine2025-06-05